- About us
- You are
- Patients and relatives
- To be cared for and supported
- Become an expert patient
- Professionnels de la santé
- Care
- Research
- Our research teams
- Molecular pathology
- Functional precision medicine for leukemia
- Normal and pathological hematopoiesis
- Niche, Cancer, and Radiation in Hematopoiesis
- Population Evolution and Interaction Particle Systems
- Translational Immunology in Immunotherapy and Hematology (TIGITH)
- Identification and targeting of extrinsic regulators of myeloid malignancies
- Lymphoid niches, Chemokines and Immuno-hematological syndromes
- Molecular Mechanisms of Acute Myeloid Leukemia Development
- Chronic Myeloid Malignancies, Microenvironment & Translational Research
- Leukemia & Niche Dynamics
- Genetic and Epigenetic control of Normal and Malignant Hematopoiesis
- Stem cell dysfunction and secondary AML
- Biostatistics and clinical epidemiology
- Our technological platforms
Accueil Biostatistics and clinical epidemiologyBiostatistics and clinical epidemiology
...Research themes
By combining the activities of the research unit with expertise in data management and statistics, the department provides answers to questions raised by investigators through research protocols.
By developing new statistical methods or improving existing ones, the department contributes to improving patient care and, more broadly, to strengthening public health.
Team members
Souad BENARABData managerCendrine CHAFFAUTBiostatisticianKristell DESSEAUXBiostatisticianCorinne NYANOUData managerClaire PACHECOData managerEmilia STANBioinformaticianAnouk WALTER PETRICHBiostatisticianBrigitte GUILLONData scientistNoémie BIGOTBiostatisticianClémence GUILHINResearch EngineerValentin VINNATResearch EngineerOlivier HASSANALYData scientistAndrei BONTENetwork AdministratorDéborah AZOULAYSecretary/Administrative ManagerHélène BATIGAData entry operatorScientific publications
A predictive classifier of poor prognosis in transplanted patients with juvenile myelomonocytic leukemia: a study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.
Déborah Meyran & al, Haematologica, 2024Lire la publicationNilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia.
Yves Chalandon & al, Blood, 2024Lire la publicationMulti-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.
Pierre Hirsch & al, Blood Cancer J, 2024Lire la publicationClinical studies
Observational cohort study of patients aged over 60 years with acute myeloid leukemia (AML) receiving standard chemotherapy treatment with idarubicin-cytarabine
Combination of anti-PD1 antibody with reinfusion of Tisagenlecleucel in children, adolescents, and young adults with acute lymphoblastic leukemia
Phase 3 study comparing sequential induction chemotherapy with sequential conditional induction chemotherapy in patients with acute myeloid leukemia in the CBF group
Treatment protocol for standard-risk B-cell acute lymphoblastic leukemia in children
Multicenter protocol for the treatment of acute lymphoblastic leukemia (ALL) in young adults (18-59) – GRAALL 2005-GRAALL-R GRAAPH 2005
Evaluation of residual disease in cryopreserved ovarian fragments prior to allogeneic hematopoietic stem cell transplantation in patients in complete remission from acute leukemia.
Clono-specific residual disease in acute myeloid leukemia
National protocol for the treatment of acute lymphoblastic leukemia (ALL) in children and adolescents
Study of the expansion and persistence of anti-CD19 CAR-T lymphocytes (CTL019) using HIV PCR during treatment of relapsed or refractory pediatric B-cell acute lymphoblastic leukemia
Randomized Phase III study of Decitabine with or without Hydrea versus Hydrea alone in patients with advanced chronic myelomonocytic leukemia
Acute Myeloid Leukemia: Retrospective Real-World Clinical and Biological Database, Updated
Primary plasma cell leukemias: a phase II prospective study combining Daratamumab with chemotherapy and intensive treatment plus autologous transplantation
Join us
Every year, we welcome interns from master’s programs and engineering schools specializing in:
Biostatistics, Computer Science,
Risk Management and Financial Engineering,
AI Computer Science,
Applied Mathematics,
Biological Engineering.
Suivez nos actions en vous inscrivant à la lettre d'information de l’institut
- Become an expert patient
- To be cared for and supported
- Patients and relatives